Propranolol Treatment for Hemangioma of Infancy: Risks and Recommendations

Authors


Address correspondence to Leslie P. Lawley, M.D., Department of Dermatology, Emory University School of Medicine, 1365-A Clifton Road, NE, Suite 1400, Atlanta, GA 30322, or e-mail: lpotter@emory.edu.

Abstract

Abstract:  Hemangioma of infancy is a condition that may be associated with significant morbidity. While evidence most supports the use of corticosteroids, there is no well-defined or Federal Drug Administration (FDA)-approved systemic therapy for hemangioma of infancy. All currently used treatments have significant risks. Dramatic improvement of complicated hemangioma of infancy to propranolol was recently reported, but details for initiating therapy, monitoring, and potential risks were not included. We present two infants treated with propranolol, who suffered complications and propose a treatment protocol to minimize potential adverse events.

Ancillary